Prevention of graft-vs-host reaction induced immunodeficiency by treatment with splenopentin (DAc-SP5).
Early experiments had shown that splenopentin, the active part of the splenic hormone splenin, stimulates the differentiation of virgin B- and T-lymphocytes and significantly enhanced the reconstitution of immune reactions after immune suppression. The present study investigates the influence of splenopentin on the course of the graft-vs-host reaction (GVHR). The experimental model used were adult hybrid mice which received intravenously parental spleen cells. During the GVHR which has an chronical course in the strain combinations used a short stimulatory phase is followed by a long-lasting immunosuppression detected by antibody formation against sheep erythrocytes. Furthermore, the splenomegaly in the first weeks after spleen cell injection changed to a drastic decrease of the spleen weight up to strongly beyond normal values. Continuous treatment with splenopentin significantly prevented both symptoms of the GVHR: The suppression of the antibody formation was diminished widely, and no loss of spleen weight occurred. Furthermore, during the stimulatory phase anti-DNA-autoantibodies were produced in the untreated animals, while the splenopentin therapy prevented this reaction. During the further course of the experiment no increase of autoantibody production was detected later on.[1]References
- Prevention of graft-vs-host reaction induced immunodeficiency by treatment with splenopentin (DAc-SP5). Eckert, R., Volk, H.D., Diezel, W., Maciewski, J., Hiepe, F., Forner, K., von Baehr, R. Allergie und Immunologie. (1989) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
